HAP Trading’s Adaptimmune Therapeutics ADAP Stock Holding History

HAP Trading’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,100	Closed	-$3K	–	2169
2021 Q4	$3K	Buy	15,100 +3,000	+25%	+$13.7K	﹤0.01%	2302
2021 Q3	$5K	Sell	12,100 -2,200	-15%	-$9.87K	﹤0.01%	2159
2021 Q2	$5K	Buy	+14,300	New	+$69.4K	﹤0.01%	2131
2021 Q1	–	Sell	-10,200	Closed	-$20K	–	1873
2020 Q4	$20K	Buy	+10,200	New	+$55.4K	﹤0.01%	1692
2020 Q3	–	Sell	-21,300	Closed	-$23K	–	1556
2020 Q2	$23K	Buy	+21,300	New	+$134K	﹤0.01%	1264

Other funds holding ADAP

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return